To investigate the incidence and risk factors of desmopressin-induced hyponatremia during long-term treatment (1 year \[52 weeks\]) of MINIRINMELT orally disintegrating (OD) tablets 25μg/50μg (drug) for nocturia caused by nocturnal polyuria in men in daily clinical practice, and to confirm the compliance with proper use of this drug in clinical practice and to investigate the effectiveness of risk minimization activities.
Study Type
OBSERVATIONAL
Enrollment
1,087
Desmopressin (MINIRINMELT OD tablet) 25μg or 50μg, orally.
Survey Site (there may be other sites in this country)
Tokyo, Japan
Occurrence of Hyponatremia
Hyponatremia will be confirmed by the investigator if the serum sodium value is 130 mmol/L or less.
Time frame: 1 year
Time to Onset of Hyponatremia
Time frame: 1 year
Distribution of Serum Sodium Levels
Number of participants with mild decrease (serum sodium 134-130 mmol/L); moderate decrease (serum sodium \<130 mmol/L) and severe decrease (serum sodium \<=125 mmol/L) in serum sodium levels will be presented.
Time frame: 1 year
Factors Affecting the Occurrence of Desmopressin-induced Hyponatremia
To evaluate the role of the following factors in the study: adverse drug reactions (ADRs) incidence rate by background factors such as dose of MINIRINMELT 25 or 50 μg, participant age, baseline serum sodium levels, kidney function according to creatinine clearance, medical history and concomitant medications.
Time frame: 1 year
Onset Situation of Adverse Drug Reaction/Infectious Disease
An adverse event (AE) is any untoward medical occurrence that did not necessarily have a causal relationship with MINIRINMELT 25 or 50 μg. An ADR is an AE evaluated by the Investigator as being probably or possibly causally related to treatment with the MINIRINMELT 25 or 50 μg.
Time frame: 1 year
Onset Situation of Serious Adverse Events (SAEs)
A SAE is any event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect or was an important medical event that could have jeopardized the participant's safety or required medical or surgical intervention to prevent 1 of the outcomes listed above.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to 1 year
Factors Affecting Safety
To evaluate the role of the following factors in the study: adverse drug reactions incidence rate by background factors such as dose of MINIRINMELT 25 or 50 μg, participant age, baseline serum sodium levels, kidney function according to creatinine clearance, medical history and concomitant medications.
Time frame: 1 year
Compliance with proper use of drug
Number of participants with proper use of drug (MINIRINMELT 25 or 50 μg) will be presented.
Time frame: 1 year